MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB: PKTX) announces the progress of screening PKX-001 for cardiometabolic disorders. “Using isolated cardiac cells, we demonstrated that PKX-001 exerts cardioprotective effects in cells that are exposed to stress induced by nutrient overload or cardiotoxic drugs. Specifically, PKX-001 minimized cardiac cell damage […]
Tag: ProtoKinetix
ProtoKinetix Begins Cardiovascular Research
MARIETTA, Ohio–(BUSINESS WIRE)–ProtoKinetix, Incorporated (www.protokinetix.com) (the “Company” or “ProtoKinetix”) (OTCQB:PKTX) Is pleased to announce the launch of a proof of concept study in the field of cardiovascular sciences. Dr. Thomas Pulinilkunnil, Associate Professor, Department of Biochemistry and Molecular Biology, Dalhousie University is the principal investigator on this project. Pulinilkunnil laboratory […]



